Back to bradykinin

Almost a decade after Bradycor was terminated during Phase II development because of insufficient efficacy and fears of toxicity, Xytis Pharmaceuticals Ltd. is taking another shot at bradykinin inhibition. Xytis has in-licensed a small molecule bradykinin B2 receptor blocker, Anatibant, from Fournier Pharma. The deal gives Xytis its second and most advanced product.

Fournier granted Xytis an exclusive worldwide license to Anatibant (LF-16-0687MF) to treat traumatic brain injury (see BioCentury, June 20). The compound, which is delivered via subcutaneous injection, has completed some Phase I testing and has Orphan Drug designation in the U.S. and Europe, and Fast Track designation in the U.S. ...